Avtal | $24,000,000 | (Mar 20, 2026)
games2gether | $5,202,945 | (Mar 20, 2026)
Claros | $30,000,000 | (Mar 20, 2026)
Certified by Founder
Lodge
Shinobi Therapeutics
start up
United States
- South San Francisco, CA
- 13/12/2023
- Series A
- $51,000,000
Shinobi Therapeutics is developing a new class of hypoimmune CD8ab iPS-T cells for cancer and beyond by using immune evasion to unlock the full potential of iPSCs.
- Industry Biotechnology Research
- Website https://www.shinobitx.com/
- LinkedIn https://www.linkedin.com/company/shinobitx/about/
Related People
Dan KempFounder
United States -
New York City Metropolitan Area
Accomplished BioPharma Executive with experience in drug discovery (Novartis), translational and clinical development (Merck), sell-side, buy-side and M&A transactional BD (Takeda), Executive oversight (GammaDelta Therapeutics, Adaptate Therapeutics) and Operational Leadership (Cell Therapies at Takeda).
Latent | $80,000,000 | (Mar 20, 2026)
Corridor | $25,000,000 | (Mar 20, 2026)
RunSybil | $40,000,000 | (Mar 20, 2026)
Ezra AI Labs | $3,200,000 | (Mar 20, 2026)
Parallel(FRANCE) | $20,000,000 | (Mar 20, 2026)
Health Universe | $6,000,000 | (Mar 20, 2026)
PADO AI | $6,000,000 | (Mar 20, 2026)
Edra | $30,000,000 | (Mar 20, 2026)
Chalkie AI | $4,000,000 | (Mar 20, 2026)
Deeptune | $43,000,000 | (Mar 20, 2026)